Tislelizumab and AG Regimen for Pancreatic Cancer
Author Information
Author(s): Feng Gao, Xue Xu, Chunhong Chen, Lili Lv
Primary Institution: Beidahuang Group General Hospital, Harbin, China
Hypothesis
Can a modified AG regimen combined with tislelizumab and olaparib lead to long-term complete responses in patients with BRCA-mutation pancreatic cancer?
Conclusion
The combination of a modified AG regimen with tislelizumab and olaparib resulted in long-term complete responses in two patients with BRCA-mutation pancreatic cancer.
Supporting Evidence
- Both patients achieved complete response after treatment.
- The complete response lasted for 39 months in case 1 and 36 months in case 2.
- The modified AG regimen showed promise for patients with BRCA mutations.
Takeaway
Two patients with a specific type of pancreatic cancer got better after using a new treatment that combined three medicines, and they stayed healthy for a long time.
Methodology
Both patients received a modified AG regimen combined with tislelizumab, followed by maintenance therapy with olaparib plus tislelizumab after 6 cycles.
Limitations
The study is limited by the small sample size.
Participant Demographics
Two patients, one male and one female, both aged 56, with BRCA1 and BRCA2 mutations respectively.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website